MaxCyte announced its Q4 2025 revenue of $7.3 million and full-year revenue of $33 million, both at the top end of preliminary guidance, despite a 15% revenue decline due to reduced purchases from key SPL customers. The company reduced cash burn by $16 million and streamlined costs in 2025, while expanding its SPL portfolio with four new agreements. For 2026, MaxCyte expects revenue between $30-32 million and plans to focus on growing its electroporation platform and assay services. The company ended 2025 with $155.6 million in cash and investments and expects at least $136 million by the end of 2026, supporting its long-term growth in cell and gene therapy markets.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
